Cargando…

Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic

Background. A large increase in multi-drug-resistant Acinetobacter baumannii, especially carbapenem-resistant strains, occurred during the first two years of the COVID-19 pandemic, posing important challenges in its treatment. Cefiderocol appeared to be a good option for the treatment of Carbapenem-...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazzitelli, Maria, Gregori, Dario, Sasset, Lolita, Trevenzoli, Marco, Scaglione, Vincenzo, Lo Menzo, Sara, Marinello, Serena, Mengato, Daniele, Venturini, Francesca, Tiberio, Ivo, Navalesi, Paolo, Cattelan, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146662/
https://www.ncbi.nlm.nih.gov/pubmed/37110408
http://dx.doi.org/10.3390/microorganisms11040984
_version_ 1785034632400470016
author Mazzitelli, Maria
Gregori, Dario
Sasset, Lolita
Trevenzoli, Marco
Scaglione, Vincenzo
Lo Menzo, Sara
Marinello, Serena
Mengato, Daniele
Venturini, Francesca
Tiberio, Ivo
Navalesi, Paolo
Cattelan, Annamaria
author_facet Mazzitelli, Maria
Gregori, Dario
Sasset, Lolita
Trevenzoli, Marco
Scaglione, Vincenzo
Lo Menzo, Sara
Marinello, Serena
Mengato, Daniele
Venturini, Francesca
Tiberio, Ivo
Navalesi, Paolo
Cattelan, Annamaria
author_sort Mazzitelli, Maria
collection PubMed
description Background. A large increase in multi-drug-resistant Acinetobacter baumannii, especially carbapenem-resistant strains, occurred during the first two years of the COVID-19 pandemic, posing important challenges in its treatment. Cefiderocol appeared to be a good option for the treatment of Carbapenem-resistant Acinetobacter baumannii (CR-Ab), but to date, the guidelines and evidence available are conflicting. Methods. We retrospectively included a group of patients with CR-Ab infections (treated with colistin- or cefiderocol-based regimens) at Padua University Hospital (August 2020–July 2022) and assessed predictors of 30-day mortality, and differences in microbiological and clinical treatment. To evaluate the difference in outcomes, accounting for the imbalance in antibiotic treatment allocation, a propensity score weighting (PSW) approach was adopted. Results. We included 111 patients, 68% males, with a median age of 69 years (IQR: 59–78). The median duration of antibiotic treatment was 13 days (IQR:11–16). In total, 60 (54.1%) and 51 (45.9%) patients received cefiderocol- and colistin-based therapy, respectively. Notably, 53 (47.7%) patients had bloodstream infections, while 58 (52.3%) had pneumonia. Colistin was combined in 96.1%, 80.4%, and 5.8% of cases with tigecycline, meropenem, and fosfomycin, respectively. Cefiderocol was combined in 13.3%, 30%, and 18.3% of cases with fosfomycin, tigecycline, and meropenem, respectively. At the baseline, the two treatment groups significantly differed in age (patients treated with colistin were significantly older), the prevalence of diabetes and obesity (more frequent in the group treated with colistin), length of stay (longer in the group receiving cefiderocol), and type of infection (BSI were more frequent in the group receiving cefiderocol). The proportion of patients who developed acute kidney injury was significantly higher in the colistin group. By using PSW, no statistically significant differences emerged for mortality or clinical and microbiological cure between the two groups. No independent predictors were detected for hospital mortality or clinical cure, while for the length of stay, the only selected predictor was age, with a non-linear effect (p-value 0.025 for non-linearity) on the prolongation of hospital stay of 0.25 days (95% CI 0.10–0.39) at increasing ages (calculated over the IQR). Conclusions. Cefiderocol treatment did not differ in terms of main outcomes and safety profile from colistin-based regimens. More prospective studies with a larger number of patients are required to confirm our results.
format Online
Article
Text
id pubmed-10146662
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101466622023-04-29 Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic Mazzitelli, Maria Gregori, Dario Sasset, Lolita Trevenzoli, Marco Scaglione, Vincenzo Lo Menzo, Sara Marinello, Serena Mengato, Daniele Venturini, Francesca Tiberio, Ivo Navalesi, Paolo Cattelan, Annamaria Microorganisms Article Background. A large increase in multi-drug-resistant Acinetobacter baumannii, especially carbapenem-resistant strains, occurred during the first two years of the COVID-19 pandemic, posing important challenges in its treatment. Cefiderocol appeared to be a good option for the treatment of Carbapenem-resistant Acinetobacter baumannii (CR-Ab), but to date, the guidelines and evidence available are conflicting. Methods. We retrospectively included a group of patients with CR-Ab infections (treated with colistin- or cefiderocol-based regimens) at Padua University Hospital (August 2020–July 2022) and assessed predictors of 30-day mortality, and differences in microbiological and clinical treatment. To evaluate the difference in outcomes, accounting for the imbalance in antibiotic treatment allocation, a propensity score weighting (PSW) approach was adopted. Results. We included 111 patients, 68% males, with a median age of 69 years (IQR: 59–78). The median duration of antibiotic treatment was 13 days (IQR:11–16). In total, 60 (54.1%) and 51 (45.9%) patients received cefiderocol- and colistin-based therapy, respectively. Notably, 53 (47.7%) patients had bloodstream infections, while 58 (52.3%) had pneumonia. Colistin was combined in 96.1%, 80.4%, and 5.8% of cases with tigecycline, meropenem, and fosfomycin, respectively. Cefiderocol was combined in 13.3%, 30%, and 18.3% of cases with fosfomycin, tigecycline, and meropenem, respectively. At the baseline, the two treatment groups significantly differed in age (patients treated with colistin were significantly older), the prevalence of diabetes and obesity (more frequent in the group treated with colistin), length of stay (longer in the group receiving cefiderocol), and type of infection (BSI were more frequent in the group receiving cefiderocol). The proportion of patients who developed acute kidney injury was significantly higher in the colistin group. By using PSW, no statistically significant differences emerged for mortality or clinical and microbiological cure between the two groups. No independent predictors were detected for hospital mortality or clinical cure, while for the length of stay, the only selected predictor was age, with a non-linear effect (p-value 0.025 for non-linearity) on the prolongation of hospital stay of 0.25 days (95% CI 0.10–0.39) at increasing ages (calculated over the IQR). Conclusions. Cefiderocol treatment did not differ in terms of main outcomes and safety profile from colistin-based regimens. More prospective studies with a larger number of patients are required to confirm our results. MDPI 2023-04-10 /pmc/articles/PMC10146662/ /pubmed/37110408 http://dx.doi.org/10.3390/microorganisms11040984 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mazzitelli, Maria
Gregori, Dario
Sasset, Lolita
Trevenzoli, Marco
Scaglione, Vincenzo
Lo Menzo, Sara
Marinello, Serena
Mengato, Daniele
Venturini, Francesca
Tiberio, Ivo
Navalesi, Paolo
Cattelan, Annamaria
Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic
title Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic
title_full Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic
title_fullStr Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic
title_full_unstemmed Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic
title_short Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic
title_sort cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant acinetobacter baumannii infections: a propensity score-weighted, retrospective cohort study during the first two years of the covid-19 pandemic
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146662/
https://www.ncbi.nlm.nih.gov/pubmed/37110408
http://dx.doi.org/10.3390/microorganisms11040984
work_keys_str_mv AT mazzitellimaria cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic
AT gregoridario cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic
AT sassetlolita cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic
AT trevenzolimarco cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic
AT scaglionevincenzo cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic
AT lomenzosara cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic
AT marinelloserena cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic
AT mengatodaniele cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic
AT venturinifrancesca cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic
AT tiberioivo cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic
AT navalesipaolo cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic
AT cattelanannamaria cefiderocolbasedversuscolistinbasedregimensforseverecarbapenemresistantacinetobacterbaumanniiinfectionsapropensityscoreweightedretrospectivecohortstudyduringthefirsttwoyearsofthecovid19pandemic